--- title: "Lipella Pharmaceuticals (LIPO) news: bankruptcy and delisting" url: "https://aibio.space/companies/lipella-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LIPO bankruptcy, delisting and offering news: Lipella's bankruptcy court approves sale of substantially all assets. Lipella Pharmaceuticals Inc." --- LIPO Lipella Pharmaceuticals Inc. OTC · United States # Lipella Pharmaceuticals (LIPO) news LIPO bankruptcy, delisting and offering news Distress · 2026-06-12 ## [Lipella's bankruptcy court approves sale of substantially all assets](https://aibio.space/news/lipellas-bankruptcy-court-approves-sale-substantially-all-assets/) A bankruptcy court approved the sale of substantially all of Lipella's assets to XRAIY LLC under an agreement dated May 14, 2026, in a chapter 11 case filed on March 30, 2026. ## Latest Lipella Pharmaceuticals news 1. 2025-06-25 Listings [Lipella Pharmaceuticals CEO says company will seek relisting after Nasdaq delisting](https://aibio.space/news/lipella-pharmaceuticals-ceo-says-company-will-seek-relisting-after/) Lipella's common stock was quoted on the OTC Pink Market under LIPO as of June 19, 2025. Nasdaq objected to securities paid to a placement agent and advisor. 2. 2025-03-28 Financings [Lipella Pharmaceuticals files to register 5,617,259 shares for resale, then sets up ATM](https://aibio.space/news/lipella-pharmaceuticals-files-register-5-617-259-shares-resale-then/) The shares come from Series B and Series C preferred stock and placement agent warrants tied to its private offerings. On April 4, 2025 Lipella added an at-the-market program of up to $2,641,881. ## Lipella Pharmaceuticals at a glance - **Ticker**: LIPO - **Listing**: OTC - **Country**: United States - **Cash, Sep 30, 2025**: $1.9 million ### Related companies - [Evolus](https://aibio.space/companies/evolus/) NASDAQ: EOLS - [Harmony Biosciences Holdings](https://aibio.space/companies/harmony-biosciences/) NASDAQ: HRMY - [Viking Therapeutics](https://aibio.space/companies/viking-therapeutics/) NASDAQ: VKTX - [Acrivon Therapeutics](https://aibio.space/companies/acrivon-therapeutics/) NASDAQ: ACRV - [Abeona Therapeutics](https://aibio.space/companies/abeona-therapeutics/) NASDAQ: ABEO - [CytoDyn](https://aibio.space/companies/cytodyn/) OTC: CYDY - [NRX Pharmaceuticals](https://aibio.space/companies/nrx-pharmaceuticals/) NASDAQ: NRXP - [RISING BIOSCIENCES INC](https://aibio.space/companies/rising-biosciences/) OTC: RBII ### Also on OTC - [Odyssey Health](https://aibio.space/companies/odyssey-health/) ODYY - [Devonian Health Group](https://aibio.space/companies/devonian-health-dvhgf/) DVHGF - [Leef Brands](https://aibio.space/companies/leef-brands/) LEEEF - [Anebulo Pharmaceuticals](https://aibio.space/companies/anebulo-pharmaceuticals/) ANEB - [NEWGEN BIOPHARMA CORP](https://aibio.space/companies/newgen-biopharma/) NEWG - [Sonendo](https://aibio.space/companies/sonendo/) SONX ## What Lipella Pharmaceuticals does Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company, incorporated in Delaware in February 2005, that develops new drugs by reformulating the active agents in existing generic drugs. Its strategy aims to combine the cost efficiencies of generic drugs with potential patent protection for its proprietary formulations, with a focus on diseases that have significant unaddressed morbidity and mortality and no approved drug therapy. The company has not yet commercialized any products. Its lead candidate, LP-10, is a reformulation of tacrolimus delivered to the bladder lumen using its metastable liposome drug delivery platform, for hemorrhagic cystitis, a complication of certain chemotherapies or pelvic radiation therapy. LP-310 is an oral liposomal tacrolimus formulation for oral lichen planus, an autoimmune oral mucosal disease, and began a Phase 2a dose-escalation trial in 2024. LP-410, an oral rinse for oral graft-versus-host disease, received orphan designation for tacrolimus in that indication on November 11, 2023. The text notes there is no FDA-approved local drug treatment for oral GVHD. | Product or program | What it is | Stage | |---|---|---| | LP-10 | Tacrolimus reformulation for topical delivery to the bladder for hemorrhagic cystitis | Phase 2a; summary results reported in the first quarter of 2023 | | LP-310 | Oral liposomal tacrolimus for oral lichen planus | Phase 2a dose-escalation trial started in 2024 | | LP-410 | Oral liposomal tacrolimus rinse for oral graft-versus-host disease | Orphan designation granted November 11, 2023; IND approval received | Summarised from the company's [10-K filed Mar 28, 2025](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000507/g084734_10k.htm). ## Lipella Pharmaceuticals annual financials | Line | FY2024 | FY2023 | |---|---|---| | Revenue | [$536,357](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000507/) | [$449,617](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000507/) | | Research and development | [$3.6 million](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000507/) | [$3.0 million](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000507/) | | Net income (loss) | [-$5.0 million](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000507/) | [-$4.6 million](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000507/) | | Cash from operations | [-$4.0 million](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000507/) | [-$3.2 million](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000507/) | | Cash and equivalents | [$2.2 million](https://www.sec.gov/Archives/edgar/data/1347242/000175392625001805/) | [$3.3 million](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000507/) | Latest balance sheet, Sep 30, 2025 (10-Q): cash and equivalents $1.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Lipella Pharmaceuticals Did Lipella Pharmaceuticals file for bankruptcy? Our latest story on this, dated Jun 12, 2026: "Lipella's bankruptcy court approves sale of substantially all assets". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lipellas-bankruptcy-court-approves-sale-substantially-all-assets/). Was Lipella Pharmaceuticals delisted? Our latest story on this, dated Jun 25, 2025: "Lipella Pharmaceuticals CEO says company will seek relisting after Nasdaq delisting". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lipella-pharmaceuticals-ceo-says-company-will-seek-relisting-after/). Has Lipella Pharmaceuticals raised money recently? Our latest story on this, dated Mar 28, 2025: "Lipella Pharmaceuticals files to register 5,617,259 shares for resale, then sets up ATM". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lipella-pharmaceuticals-files-register-5-617-259-shares-resale-then/). What is the ticker symbol of Lipella Pharmaceuticals? Lipella Pharmaceuticals Inc. trades under the ticker LIPO on OTC. Where is Lipella Pharmaceuticals listed? Lipella Pharmaceuticals Inc. is listed on OTC. What is the SEC CIK of Lipella Pharmaceuticals? The SEC Central Index Key (CIK) for Lipella Pharmaceuticals Inc. is 1347242. Its filings are on SEC EDGAR. How many shares does Lipella Pharmaceuticals have outstanding? 4,620,837 shares as of 2025-11-13, per the cover page of its 10-Q filed 2025-11-14. Which country or territory is Lipella Pharmaceuticals listed under? Our directory records Lipella Pharmaceuticals Inc. under United States. What does Lipella Pharmaceuticals do? Our directory classifies Lipella Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Lipella Pharmaceuticals? The ISIN recorded for Lipella Pharmaceuticals Inc. is US53630L2097. Does aibio.space cover Lipella Pharmaceuticals? aibio.space lists Lipella Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Lipella Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Lipella Pharmaceuticals develop? Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company, incorporated in Delaware in February 2005, that develops new drugs by reformulating the active agents in existing generic drugs. Its strategy aims to combine the cost efficiencies of generic drugs with potential patent protection for its proprietary formulations, with a focus on diseases that have significant unaddressed morbidity and mortality and no approved drug therapy. What is LP-10 from Lipella Pharmaceuticals? LP-10: Tacrolimus reformulation for topical delivery to the bladder for hemorrhagic cystitis Stage: Phase 2a; summary results reported in the first quarter of 2023. What is LP-310 from Lipella Pharmaceuticals? LP-310: Oral liposomal tacrolimus for oral lichen planus Stage: Phase 2a dose-escalation trial started in 2024. ## Investor discussion: Lipella Pharmaceuticals Members talk about Lipella Pharmaceuticals (LIPO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Lipella Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-07-15 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 1.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392626001173/g085807_8k.htm) 2. 2026-03-31 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 1.03). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392626000577/g085465_ex99-1.htm) 3. 2025-10-06 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1347242/000135445725000985/xslF25X02/primary_doc.xml) 4. 2025-06-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392625001003/g084855_ex99-1.htm) 5. 2025-06-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000984/g084852_ex99-1.htm) 6. 2025-05-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000856/g084822_8k.htm) 7. 2025-04-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000623/g084773_8k.htm) 8. 2025-03-28 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000509/g084740_s3.htm) 9. 2025-03-11 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000425/g084727_8k.htm) 10. 2025-02-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000276/g084711_8k.htm) 11. 2025-01-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392625000078/g084656_8k.htm) 12. 2024-12-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392624002189/g084615_8k.htm) 13. 2024-12-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392624002052/g084587_8k.htm) 14. 2024-11-07 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392624001824/g084539_8k.htm) 15. 2024-11-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1347242/000175392624001793/g084523_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:LIPO on TradingView](https://www.tradingview.com/symbols/OTC-LIPO/). ## SEC filings and registration - **SEC name**: Lipella Pharmaceuticals Inc. - **CIK**: 1347242 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: LIPO (None) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 400 N LEXINGTON ST, PITTSBURGH, PA, 15208 - **Phone**: 412-901-0315 - **Shares outstanding**: 4,620,837 as of 2025-11-13 (10-Q filed 2025-11-14) - **Former names**: LIPELLA PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1347242/000175392626001173/g085807_8k.htm) filed 2026-07-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1347242/000175392626000577/g085465_8k.htm) filed 2026-03-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1347242/000175392626000265/g085113_8k.htm) filed 2026-02-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1347242/000175392625001805/g084988_10q.htm) filed 2025-11-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1347242/000175392625001636/g084980_8k.htm) filed 2025-10-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1347242/000175392625001602/g084974_8k.htm) filed 2025-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1347242/000175392625001525/g084955_8k.htm) filed 2025-09-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1347242/000175392625001347/g084907_10q.htm) filed 2025-08-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001347242), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Lipella Pharmaceuticals Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker LIPO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Lipella Pharmaceuticals Inc. - **Ticker**: LIPO - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US53630L2097 - **Last quote in directory**: 2026-10-20 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-LIPO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lipella-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lipella Pharmaceuticals (LIPO) news: bankruptcy and delisting", 2026-10-31, https://aibio.space/companies/lipella-pharmaceuticals/